Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 12/20 | 0.43 |
| ▸ | RARB | P10826 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | RARA | P10276 | 2/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14226537 | 0.95 | KIF11 (0.39) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL15783713 | 0.94 | KIF11 (0.39) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL14226542 | 0.93 | KIF11 (0.38) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL17365779 | 0.90 | KIF11 (0.36) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL13636540 | 0.90 | KIF11 (0.43) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL12624715 | 0.90 | KIF11 (0.37) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL19711843 | 0.90 | KIF11 (0.44) | KIF11CYP11B1CYP11B2 | |
| SCHEMBL7731510 | 0.89 | DAO (0.34) | KIF11MAOB | |
| SCHEMBL19711845 | 0.89 | KIF11 (0.40) | KIF11RARBCYP11B1CYP11B2RARA | |
| SCHEMBL14226535 | 0.89 | KIF11 (0.40) | KIF11RARBCYP11B1CYP11B2RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842974-B1 | COMPOUND HAVING FOUR POLYMERIZABLE GROUPS, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-20170355906-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | DIC CORPORATION (JP) | 2017-12-14 | — | — | US | disclosed |
| US-8821757-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8821757-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20120314146-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
| US-20120314146-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120314146-A1 | LIQUID-CRYSTALLINE MEDIUM | NEFM, CHRM1, AQP1 | KIF11 650/4885RARB 1740/4885CYP11B1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.